BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
Breaking News: Topic alerts now available for all BioWorld subscribers
See today's BioWorld Science
Home
» S-086 reduces blood pressure and ameliorates organ injury in spontaneously hypertensive rats
To read the full story,
subscribe
or
sign in
.
Cardiovascular
S-086 reduces blood pressure and ameliorates organ injury in spontaneously hypertensive rats
Jan. 16, 2024
No Comments
Researchers from Shenzhen Salubris Pharmaceuticals Co. Ltd. have published preclinical data for the angiotensin receptor neprilysin (ARN) inhibitor S-086, currently in clinical development for the treatment of hypertension.
BioWorld Science
Cardiovascular
